CHMP Endorses J&J's Rybrevant-Lazcluze Combo for Use in NSCLC

Johnson & Johnson (JNJ) announced that the EMA’s Committee for Medicinal Products for Human Use (“CHMP”) recommended approving the combination of its intravenously administered EGFR/MET inhibitor Rybrevant (amivantamab) and oral EGFR-TKI inhibitorLazcluze (lazertinib) for use in certain patients with non-small cell lung cancer (NSCLC).The CHMP has recommended the Rybrevant-Lazcluze combination as a first-line treatment for adult patients with locally advanced or metastatic NSCLC with EGFR exon 19 deletions ...